 Etrolizumab is an integrin receptor antagonist that targets beta 7 integrins.Etrolizumab has shown efficacy in phase 2 trials as well.The hope is that etrolizumab can show similar efficacy to natalizumab while avoiding the specific cellular target that is believed to have caused the instances of progressive multifocal leukoencephalopathy.